| Related Articles |
Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure.
Heart Fail Clin. 2014 Oct;10(4):565-576
Authors: Cole RT, Gupta D, Butler J
Abstract
The origins of the hydralazine/isosorbide dinitrate (H+ISDN) combination therapy are rooted in the first large-scale clinical trial in heart failure: V-HeFT I. Initially utilized for the balanced vasodilatory properties of each drug, we now know there is "more to the story." In fact, the maintenance of the nitroso-redox balance may be the true mechanism of benefit. Since the publication of V-HeFT I 30 years ago, H+ISDN has been the subject of much discussion and debate. Regardless of the many controversies surrounding H+ISDN, one thing is clear: therapy is underutilized and many patients who could benefit never receive the drugs. Ongoing physician and patient education are mandatory to improve the rates of H+ISDN use.
PMID: 25217432 [PubMed - as supplied by publisher]